IMR Press / FBL / Volume 14 / Issue 10 / DOI: 10.2741/3476

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Article

Dipeptidyl peptidase 8 and 9 - guilty by association?

Show Less
1 School of Biological Sciences, Flinders University, GPO BOX 2100, Adelaide 5001, South Australia, Australia
2 Department of Haematology and Genetic Pathology, Flinders Medical Centre, Bedford Park 5042, South Australia, Australia
Front. Biosci. (Landmark Ed) 2009, 14(10), 3619–3633; https://doi.org/10.2741/3476
Published: 1 January 2009
(This article belongs to the Special Issue Dipeptidyl peptidase IV and related molecules in health and disease)
Abstract

Dipeptidyl peptidases (DP) 8 and 9 are members of the DPIV enzyme family. Other members include DPIV, fibroblast activation protein (FAP) and the non-enzymes DP6 and DP10. DPIV family members have diverse biological roles, and have been implicated in a range of diseases including diabetes, cancer, inflammatory bowel disease, multiple sclerosis (MS), arthritis and asthma. While DP8/9 biological functions are yet to be established, they have been predicted to have similar roles to the other DPs due to high sequence similarities within the active site of the enzymes. While there is mounting evidence towards the involvement of DP8 and/or DP9 in innate and acquired immunity, direct proof for the link between DP8 and DP9 and human disease is yet to be definitively shown, thus DP8 and 9 proteins remain guilty by association.

Share
Back to top